SCHEMBL2270048

SCHEMBL2270048

COC1CCN(C(=O)CC2CCN(c3ncc(C(=O)NC4CC4)cc3NC(=O)c3cccc(Cl)c3)CC2)CC1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CXCR3 P49682 3/20 0.52
CDK2 P24941 6/20 0.42
CCNA2 P20248 2/20 0.42
CCNE1 P24864 4/20 0.42
L3MBTL1 Q9Y468 1/20 0.40
CRHR1 P34998 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
FNTA P49354 1/20 0.39
FNTB P49356 1/20 0.39
HTR1A P08908 1/20 0.38
HTR7 P34969 1/20 0.38
RORC P51449 1/20 0.38
GRM5 P41594 2/20 0.38
SMO Q99835 1/20 0.38
GPR6 P46095 1/20 0.38
USP2 O75604 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2269790 0.92 CXCR3 (0.59) CXCR3FNTAFNTBRORCSMO
SCHEMBL12516565 0.91 CXCR3 (0.52) CXCR3FNTAFNTBRORCSMO
SCHEMBL2279278 0.91 CXCR3 (0.53) CXCR3CDK2CCNE1L3MBTL1CRHR1
SCHEMBL14659435 0.89 CXCR3 (0.42) CXCR3CDK2CCNE1FNTAFNTB
SCHEMBL2267627 0.87 CXCR3 (0.50) CXCR3CDK2CCNE1L3MBTL1CRHR1
SCHEMBL2268437 0.87 CXCR3 (0.51) CXCR3FNTAFNTBRORCSMO
SCHEMBL2276470 0.86 CXCR3 (0.50) CXCR3CDK2CCNE1L3MBTL1CRHR1
SCHEMBL12516432 0.86 CXCR3 (0.57) CXCR3CDK2CCNE1L3MBTL1CRHR1
SCHEMBL12516442 0.85 CXCR3 (0.53) CXCR3CDK2CCNE1L3MBTL1CRHR1
SCHEMBL16448964 0.83 CXCR3 (0.61) CXCR3FNTAFNTBRORCSMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130029971-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-31 US claimed
WO-2011084985-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-14 WO claimed
US-8952004-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 US disclosed
US-8952004-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 US disclosed
US-8952004-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 US disclosed
US-20130029971-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-31 US disclosed
US-20130029971-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-31 US disclosed
US-20130029971-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-31 US disclosed
WO-2011084985-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130029971-A1 CXCR3 RECEPTOR ANTAGONISTS CXCR3, CXCR1, CXCR2 CXCR3 1/4885CDK2 1591/4885CCNA2 1367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.